![]() |
市场调查报告书
商品编码
1426980
流感诊断测试市场- 按测试类型(传统诊断测试{RIDT、DFAT、病毒培养、血清学测定}、分子诊断测定{RT-PCR、LAMP、NASBAT、SAMBA})、最终用途和预测,2023 年- 2032年Influenza Diagnostic Tests Market - By Test Type (Traditional Diagnostic Test {RIDT, DFAT, Viral Culture, Serological Assay}, Molecular Diagnostic Assay {RT-PCR, LAMP, NASBAT, SAMBA}), End-use & Forecast, 2023 - 2032 |
由于全球流感反覆爆发,凸显了对准确、快速诊断解决方案的迫切需求,预计 2023 年至 2032 年间,流感诊断测试市场的CAGR将达到 6.3%。根据世界卫生组织 2023 年 10 月的报告,每年约有 10 亿例季节性流感病例,其中包括 300-500 万例重症病例。当全世界都在努力应对流感的持续威胁时,诊断测试有助于早期发现、有效治疗和遏制病毒。
诊断工具的不断发展,包括分子检测、快速抗原检测和核酸扩增技术,提高了流感诊断的精确度和效率。对更灵敏、更特异和更快速的诊断方法的追求鼓励了研发投资。
流感诊断测试产业根据测试类型、最终用途和地区进行细分。
分子诊断分析领域有望在预测期内大幅增长,因为聚合酶链反应(PCR)和核酸扩增测试在检测流感病毒方面具有高灵敏度和特异性。这种精确度对于准确和及时的诊断非常重要,可以迅速启动适当的治疗和遏制措施。对快速、可靠的诊断解决方案的需求不断增长,加上分子诊断技术的进步,促进了该领域的成长。
由于在推进诊断技术和方法方面发挥重要作用,研究实验室部门将在 2023 年至 2032 年期间为市场带来可观的收入。研究实验室帮助开发创新的诊断方法和不断改进现有的测试平台。研究实验室对卓越诊断准确性的追求直接转化为更可靠、更有效率的测试的可用性,从而提高了诊断能力的整体标准。
由于快速的城市化、医疗保健意识的提高以及政府积极主动对抗传染病,亚太地区流感诊断测试行业预计到 2032 年将显着增长。流感发生率的增加,加上人们对传染病的经济影响的认识不断提高,刺激了对精确诊断解决方案的需求。此外,医疗机构、政府和诊断公司之间的策略合作有助于更有效地应对流感疫情,有利于区域市场前景。
Influenza Diagnostic Tests Market is estimated to witness 6.3% CAGR between 2023 and 2032, owing to the recurrent global outbreaks of influenza that highlight the critical need for accurate and rapid diagnostic solutions. As per WHO October 2023 report, there were approximately a billion cases of seasonal influenza annually, which included 3-5 million cases of severe illness. As the world grapples with the ongoing threat of influenza, diagnostic tests help in early detection, effective treatment, and containment of the virus.
The continual evolution of diagnostic tools, including molecular assays, rapid antigen tests, and nucleic acid amplification techniques, enhances the precision and efficiency of influenza diagnosis. The quest for more sensitive, specific, and quicker diagnostic methods encourages R&D investments.
Influenza diagnostic tests industry is segmented on the basis of test type, end-use, and region.
Molecular diagnostic assays segment is poised for substantial growth over the forecast period, as polymerase chain reaction (PCR) and nucleic acid amplification tests, offer high sensitivity and specificity in detecting influenza viruses. This precision is important for accurate and timely diagnosis, allowing for prompt initiation of appropriate treatments and containment measures. The growing demand for rapid and reliable diagnostic solutions, coupled with advancements in molecular diagnostic technologies, contribute to the segment growth.
Research laboratories segment will generate notable revenues for the market during 2023-2032, owing to the instrumental role in advancing diagnostic technologies and methodologies. Research laboratories help in the development of innovative diagnostic assays and the continual improvement of existing testing platforms. The pursuit of excellence in diagnostic accuracy within research laboratories directly translates into the availability of more reliable and efficient tests, elevating the overall standard of diagnostic capabilities.
Asia Pacific influenza diagnostic tests industry is slated to witness a significant growth rate through 2032, attributed to rapid urbanization, increased healthcare awareness, and proactive government initiatives to combat infectious disease. The increasing incidence of influenza, coupled with a rising awareness of the economic impact of infectious diseases, fuels the demand for precise diagnostic solutions. Moreover, strategic collaborations between healthcare institutions, governments, and diagnostic companies contribute to a more efficient response to influenza outbreaks, favoring the regional market outlook.